Article thumbnail

The Rostral Migratory Stream Plays a Key Role in Intranasal Delivery of Drugs into the CNS

By Robert A. Scranton, Lauren Fletcher, Shane Sprague, David F. Jimenez and Murat Digicaylioglu
Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2004). Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I.
  2. (1996). Alvarez-Buylla A
  3. (1981). Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat.
  4. (1962). Are new neurons formed in the brains of adult mammals?
  5. (1994). Astrocyte responses to CNS injury.
  6. (2010). Astrocytes: biology and pathology.
  7. (1965). Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats.
  8. (1969). Autoradiographic and histological studies of postnatal neurogenesis. IV. Cell proliferation and migration in the anterior forebrain, with special reference to persisting neurogenesis in the olfactory bulb.
  9. (2009). Blood vessels form a migratory scaffold in the rostral migratory stream.
  10. (2000). Consequences of neural cell adhesion molecule deficiency on cell migration in the rostral migratory stream of the mouse.
  11. (2011). Cytoarchitecture of the lateral ganglionic eminence and rostral extension of the lateral ventricle in the human fetal brain.
  12. (1995). Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs.
  13. (2010). Erythropoietin in stroke: quo vadis.
  14. (2010). Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders.
  15. (2008). From nose to brain: understanding transport capacity and transport rate of drugs.
  16. (2007). Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension.
  17. (2009). Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats.
  18. (2001). Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage.
  19. (2010). Intranasal administration of PEGylated transforming growth factor-alpha improves behavioral deficits in a chronic stroke model.
  20. (2008). Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease.
  21. (2009). Intranasal delivery of cells to the brain.
  22. (2009). Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke.
  23. (2009). Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation.
  24. (2008). Intranasal delivery of insulin and a nitric oxide synthase inhibitor in an experimental model of amyotrophic lateral sclerosis.
  25. (2010). Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT4 to the CNS.
  26. (2009). Intranasal delivery to the central nervous system: mechanisms and experimental considerations.
  27. (2008). Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults.
  28. (2006). Intranasal insulin administration: a method for dissociating central and peripheral effects of insulin.
  29. (2008). Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy.
  30. (2010). Intranasal M cell uptake of nanoparticles is independently influenced by targeting ligands and buffer ionic strength.
  31. (2010). Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses.
  32. (2004). Is nose-to-brain transport of drugs in man a reality?
  33. (2009). Lack of association between PSA-NCAM expression and migration in the rostral migratory stream of a Huntington’s disease transgenic mouse model.
  34. (2003). Neural stem cells and the regulation of adult neurogenesis.
  35. (2010). New neurons clear the path of astrocytic processes for their rapid migration in the adult brain.
  36. (2007). Olfactory bulb hypoplasia in Prokr2 null mice stems from defective neuronal progenitor migration and differentiation.
  37. (2005). Olfactory bulbectomy in mice induces alterations in exploratory behavior.
  38. (2010). Proliferation but not migration is associated with blood vessels during development of the rostral migratory stream.
  39. (2010). Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease.
  40. (1995). Quantitative analysis of the olfactory pathway for drug delivery to the brain.
  41. (1991). Rapid activation of astrocyte-specific expression of GFAP-lacZ transgene by focal injury.
  42. (2009). Recombinant human erythropoietin in the treatment of acute ischemic stroke.
  43. (1993). Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone.
  44. (1989). Spatiotemporal patterns of the astroglial proliferation in rat brain injured at the postmitotic stage of postnatal development: a combined immunocytochemical and autoradiographic study.
  45. (1999). Tangential migration of young neurons arising from the subventricular zone of adult rats is impaired by surgical lesions passing through their natural migratory pathway.
  46. (2001). The melanocortin melanocyte-stimulating hormone/adrenocorticotropin(4-10) decreases body fat in humans.
  47. (2011). Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease.
  48. (2010). Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.